Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation

Abiraterone is a selective inhibitor of androgen biosynthesis approved for the treatment of metastatic patients affected by castration-resistant or castration-sensitive prostate cancer. Intriguingly, clinical data revealed that abiraterone also delayed disease progression in bone improving bone-rela...

Full description

Bibliographic Details

Main Authors:	Michele Iuliani, Sonia Simonetti, Giulia Ribelli, Silvia Cavaliere, Bruno Vincenzi, Giuseppe Tonini, Francesco Pantano, Daniele Santini
Format:	Artigo
Language:	Inglês
Published:	MDPI AG 2022-09-01
Series:	Biomedicines
Subjects:	abiraterone castration-resistant prostate cancer (CRPC) cells osteoblasts androgen receptor
Online Access:	https://www.mdpi.com/2227-9059/10/9/2154
Tags:	Add Tag No Tags, Be the first to tag this record!